Sangamo Therapeutics Management
Management criteria checks 4/4
Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 8.5 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $1.02M. The average tenure of the management team and the board of directors is 3.3 years and 5.1 years respectively.
Key information
Sandy Macrae
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 29.9% |
| CEO tenure | 8.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%
Dec 08
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Nov 20What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Oct 23Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Oct 21There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$135m |
| Jun 30 2024 | n/a | n/a | -US$248m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
Compensation vs Market: Sandy's total compensation ($USD2.39M) is about average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Sandy's compensation has been consistent with company performance over the past year.
CEO
Sandy Macrae (61 yo)
8.5yrs
Tenure
US$2,392,272
Compensation
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | US$2.39m | 0.20% $ 1.0m | |
| Senior VP | 5.5yrs | US$1.06m | 0.040% $ 204.5k | |
| Senior VP & Chief Development Officer | 5.9yrs | US$1.03m | 0.046% $ 235.4k | |
| Head of Research & Technology | 1.1yrs | no data | 0.019% $ 99.6k | |
| Head of Corporate Communications & Investor Relations Officer | no data | no data | no data | |
| Senior VP | 3.3yrs | no data | 0.044% $ 224.3k | |
| Head of Technical Operations | 1.6yrs | no data | no data | |
| Head of Business Development & Alliance Management | less than a year | no data | no data | |
| Scientist II - Discovery & Translational Research | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data |
3.3yrs
Average Tenure
55yo
Average Age
Experienced Management: SGMO's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | US$2.39m | 0.20% $ 1.0m | |
| Independent Chairwoman of the Board | 10.5yrs | US$99.28k | 0.030% $ 154.6k | |
| Independent Director | 8.5yrs | US$80.53k | 0.024% $ 122.5k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Independent Director | 6.5yrs | US$76.78k | 0.025% $ 128.7k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data |
5.1yrs
Average Tenure
66.5yo
Average Age
Experienced Board: SGMO's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sangamo Therapeutics, Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Gregory Harrison | BofA Global Research |
| Jonathan Aschoff | Brean Capital |